KYPROLIS 30 mg/15mL
carfilzomib · INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION · Onyx Pharmaceuticals, Inc.
KYPROLIS is a injection, powder, lyophilized, for solution containing carfilzomib at 30 mg/15mL, taken intravenous. Manufactured by Onyx Pharmaceuticals, Inc..
Key Facts
- Brand Name
- KYPROLIS
- Generic Name
- carfilzomib
- NDC Code (Product)
76075-102- Manufacturer
- Onyx Pharmaceuticals, Inc.
- Strength
- 30 mg/15mL
- Dosage Form
- INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION
- Route
- INTRAVENOUS
- Marketing Status
- Application #
- NDA202714
- Drug Class
- Proteasome Inhibitor [EPC]
- Marketing Start
- 07/15/2016
Recall History
No Recall HistorySide Effects Reported to FDA
FDA FAERS database · These are reported events, not confirmed side effects
Frequently Asked Questions
What is KYPROLIS used for?
KYPROLIS contains carfilzomib. It is a injection, powder, lyophilized, for solution taken intravenous. Consult your doctor for specific uses.
Is KYPROLIS a controlled substance?
KYPROLIS is not classified as a controlled substance by the DEA.
What is the generic name for KYPROLIS?
The generic name for KYPROLIS is carfilzomib. There are no other listed brand versions of carfilzomib.
What is the NDC code for KYPROLIS 30 mg/15mL?
The NDC (National Drug Code) for KYPROLIS 30 mg/15mL is 76075-102, listed by Onyx Pharmaceuticals, Inc..
Other KYPROLIS Dosages
Not medical advice. Always consult your doctor or pharmacist before making any medication decisions.
Data from openFDA · Public domain (CC0 1.0)